| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
103.12(B) |
| Last
Volume: |
259,279 |
Avg
Vol: |
765,410 |
| 52
Week Range: |
$692.45 - $993.95 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
168,566 |
236,471 |
279,472 |
438,206 |
| Total Sell Value |
$164,437,486 |
$226,505,895 |
$262,153,799 |
$373,147,368 |
| Total People Sold |
8 |
14 |
16 |
18 |
| Total Sell Transactions |
15 |
42 |
60 |
120 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sing George L |
Director |
– • – |
2020-08-31 |
4 |
S |
$610.45 |
$6,120,555 |
D/D |
(10,000) |
54,415 |
|
18% |
|
| Poon Christine A |
Director |
– • – |
2020-08-28 |
4 |
S |
$598.91 |
$24,048,715 |
D/D |
(40,000) |
1,433 |
|
17% |
|
| Poon Christine A |
Director |
– • – |
2020-08-28 |
4 |
OE |
$25.45 |
$1,137,550 |
D/D |
40,000 |
41,433 |
|
- |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2020-08-27 |
4 |
D |
$614.87 |
$3,276,027 |
D/D |
(5,328) |
19,110 |
|
- |
|
| Larosa Joseph J |
EVP General Counsel and Secret |
• – – |
2020-08-27 |
4 |
OE |
$52.03 |
$520,300 |
D/D |
10,000 |
21,241 |
|
- |
|
| Sing George L |
Director |
– • – |
2020-08-25 |
4 |
S |
$612.00 |
$612,000 |
I/I |
(1,000) |
3,700 |
|
21% |
|
| Sing George L |
Director |
– • – |
2020-08-25 |
4 |
S |
$600.36 |
$19,888,518 |
D/D |
(32,750) |
64,415 |
|
21% |
|
| Sing George L |
Director |
– • – |
2020-08-25 |
4 |
OE |
$273.67 |
$3,489,293 |
D/D |
12,750 |
97,165 |
|
- |
|
| Van Plew Daniel P |
EVP & General Mgr Industrial O |
• – – |
2020-08-25 |
4 |
S |
$609.71 |
$16,560,738 |
D/D |
(27,109) |
20,001 |
|
21% |
|
| Sing George L |
Director |
– • – |
2020-08-24 |
4 |
S |
$592.27 |
$11,894,577 |
D/D |
(20,037) |
84,415 |
|
21% |
|
| Sing George L |
Director |
– • – |
2020-08-24 |
4 |
OE |
$177.82 |
$1,784,779 |
D/D |
10,037 |
104,452 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2020-08-21 |
4 |
S |
$617.18 |
$617,180 |
D/D |
(1,000) |
5,643 |
|
20% |
|
| Sing George L |
Director |
– • – |
2020-08-21 |
4 |
S |
$605.04 |
$12,080,040 |
D/D |
(19,963) |
94,415 |
|
20% |
|
| Sing George L |
Director |
– • – |
2020-08-21 |
4 |
OE |
$57.11 |
$1,168,071 |
D/D |
9,963 |
114,078 |
|
- |
|
| Mccourt Marion |
SVP Commercial |
• – – |
2020-08-20 |
4 |
AS |
$612.15 |
$612,150 |
D/D |
(1,000) |
13,963 |
|
-22% |
|
| Mccourt Marion |
SVP Commercial |
• – – |
2020-08-20 |
4 |
OE |
$342.93 |
$342,930 |
D/D |
1,000 |
14,963 |
|
- |
|
| Van Plew Daniel P |
EVP & General Mgr Industrial O |
• – – |
2020-08-20 |
4 |
D |
$614.09 |
$29,409,384 |
D/D |
(47,891) |
47,110 |
|
- |
|
| Van Plew Daniel P |
EVP & General Mgr Industrial O |
• – – |
2020-08-20 |
4 |
OE |
$179.13 |
$13,434,750 |
D/D |
75,000 |
95,001 |
|
- |
|
| Sing George L |
Director |
– • – |
2020-08-20 |
4 |
S |
$615.48 |
$12,955,042 |
D/D |
(21,000) |
104,415 |
|
22% |
|
| Sing George L |
Director |
– • – |
2020-08-20 |
4 |
OE |
$57.11 |
$571,100 |
D/D |
10,000 |
114,415 |
|
- |
|
| Vagelos P Roy |
Director |
– • – |
2020-08-11 |
4 |
AS |
$594.20 |
$20,174,355 |
I/I |
(33,460) |
50,192 |
|
-18% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-08-04 |
4 |
AS |
$654.46 |
$455,504 |
D/D |
(696) |
23,973 |
|
-24% |
|
| Ryan Arthur F |
Director |
– • – |
2020-08-03 |
4 |
AS |
$633.78 |
$64,193 |
D/D |
(100) |
28,543 |
|
-22% |
|
| Yancopoulos George |
President and Chief Scientific |
• • – |
2020-07-27 |
4 |
GD |
$0.00 |
$0 |
I/I |
57,465 |
0 |
|
- |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2020-07-21 |
4 |
AS |
$636.56 |
$2,381,317 |
D/D |
(3,709) |
17,501 |
|
-20% |
|
1366 Records found
|
|
Page 26 of 55 |
|
|
4.45 (0.45%) 
